Harmony Biosciences Holdings (HRMY) is back in focus after reporting fourth quarter and full year 2025 earnings, reaffirming 2026 WAKIX revenue guidance, and highlighting fresh FDA approval for pediatric cataplexy in narcolepsy.

Despite strong WAKIX revenue guidance and fresh pediatric approval, Harmony Biosciences’ recent share price performance has been weak, with a 30 day share price return of 23% and a 1 year total shareholder return of 16%. This suggests momentum has been fading even as news flow remains busy around earnings, guidance, FDA decisions and litigation settlements.

If this mix of earnings surprises and regulatory updates has you thinking about where else growth stories might emerge in neurology, take a look at our screener of 27 healthcare AI stocks as potential next ideas to research.

With HRMY shares posting a 1 year total return decline of 16.7% even as analysts’ average price targets sit well above the last close, is the stock on sale today, or is the market already baking in future growth?

Most Popular Narrative: 39.7% Undervalued

Harmony Biosciences’ most followed valuation narrative pegs fair value at $47.30, well above the recent $28.54 close, and frames that gap around WAKIX cash flows, late stage assets, and legal timing on generics.

Harmony is positioned to capture new sources of revenue and reduce product concentration risk through near-term late-stage pipeline catalysts, including potential first-to-market launches for ZYN002 in Fragile X syndrome and additional pitolisant formulations (HD and GR), each aimed at high-unmet-need, orphan indications.

Want to see what kind of revenue ramp, margin profile, and future earnings multiple are baked into that $47.30 figure? The narrative leans on a specific mix of growth rates, profitability assumptions, and a lower P/E than many drug peers. Curious how those moving parts add up to a near 40% gap to the current price?

Result: Fair Value of $47.30 (UNDERVALUED)

However, that 39.7% discount assumes WAKIX exclusivity holds up and key late stage assets clear regulators without major setbacks, outcomes that are far from guaranteed.

Next Steps

If this mix of optimism and caution has you on the fence, take a moment to review the full set of facts and form your own view, then see how it lines up with 4 key rewards

Looking for more investment ideas?

If Harmony has you thinking bigger about your portfolio, do not stop here. Widening your research set now can make a real difference over time.

• Target potential mispricings by scanning our list of 46 high quality undervalued stocks that combine compelling fundamentals with room for the market to reassess them.
• Strengthen the core of your portfolio by reviewing solid balance sheet and fundamentals stocks screener (39 results) that pair financial resilience with clear business models.
• Get ahead of the crowd by studying our screener containing 24 high quality undiscovered gems that the broader market may not be focusing on yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.